Disease domains and associated outcome instruments for use within the OMERACT core set of outcome measures for ANCA-associated vasculitis. Bold print indicates instruments are validated for use in the OMERACT core set.
| Domain | Instruments/Measures | Comment |
|---|---|---|
| Disease activity | BVAS, BVAS/WG, BVAS3 | Validated and used in trials |
| Damage assessment | Vasculitis Damage Index | Validated for use in trials |
| Combined Damage Assessment | Under study and in use in trials | |
| End-stage renal disease | Validated for use in trials | |
| Patient-reported outcome | Medical Outcome Study Short-Form 36 | Validated and used in trials |
| Vasculitis disease-specific PRO instrument | Under development | |
| Mortality | Death | Validated and used in trials |
ANCA: antineutrophil cytoplasmic autoantibodies; BVAS: Birmingham Vasculitis Activity Score; BVAS/WG: BVAS for Wegener’s granulomatosis; BVASv.3: BVAS version 3; PRO: patient-reported outcome.